US20040076639A1 - Novel medicinal use of alpha antigen or alpha antigen gene - Google Patents

Novel medicinal use of alpha antigen or alpha antigen gene Download PDF

Info

Publication number
US20040076639A1
US20040076639A1 US10/468,456 US46845603A US2004076639A1 US 20040076639 A1 US20040076639 A1 US 20040076639A1 US 46845603 A US46845603 A US 46845603A US 2004076639 A1 US2004076639 A1 US 2004076639A1
Authority
US
United States
Prior art keywords
antigen
allergic diseases
treatment
allergic
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/468,456
Other languages
English (en)
Inventor
Yasuhiro Yasutomi
Hitoshi Mizutani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maruho Co Ltd
Original Assignee
Maruho Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maruho Co Ltd filed Critical Maruho Co Ltd
Assigned to MARUHO CO., LTD. reassignment MARUHO CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MIZUTANI, HITOSHI, YASUTOMI, YASUHIRO
Publication of US20040076639A1 publication Critical patent/US20040076639A1/en
Priority to US11/352,342 priority Critical patent/US7524675B2/en
Priority to US11/896,977 priority patent/US7622297B2/en
Priority to US12/405,844 priority patent/US20090286734A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Definitions

  • the present invention relates to novel pharmaceutical uses of ⁇ antigen derived from acid-fast bacteria (Mycobacteria) or analogs thereof or genes encoding them. More specifically, it relates to novel pharmaceutical uses of ⁇ antigen derived from Mycobacterium kansasii or analogs thereof or expression vectors containing a gene encoding them for the prevention or treatment of allergic diseases such as atopic dermatitis, asthma, allergic rhinitis and allergic conjunctivitis.
  • Mycobacteria acid-fast bacteria
  • ⁇ antigen derived from Mycobacterium kansasii or analogs thereof or expression vectors containing a gene encoding them for the prevention or treatment of allergic diseases such as atopic dermatitis, asthma, allergic rhinitis and allergic conjunctivitis.
  • Allergic diseases such as atopic dermatitis, asthma, allergic rhinitis and allergic conjunctivitis are diseases in which hypersensitive reactions occur against environmental antigens to which normal healthy people do not react and destruction and disorders of various organs occur due to the autoimmune system.
  • Th2 type cytokines such as interleukin-4 and interleukin-5 that the Th2 cells among the Th differentiate involved in cellular immune responses against antigen (Progress in Medicine 17: 19-20, 1997).
  • the elucidation of the induction mechanism and the control mechanism has important physiological and pharmacological implications, but detailed mechanisms thereof have yet to be clarified.
  • Therapies of these diseases in current use include evasion from antigen, the control of non-specific inflammatory reactions by the oral administration of antihistamines that antagonize the binding of mediators such as histamine to receptors and by topical steroid (Igaku No Ayumi (Journal of Clinical and Experimental Medicine) 180: 51-55, 1997).
  • BCG vaccine is a vaccine that utilizes an attenuated strain of Mycobacterium bovis and is the only live vaccine approved for Mycobacterium tuberculosis infections.
  • BCG vaccine has a potent adjuvant effect with little side effects, and thus has been given to many people in the world today as a safe vaccine.
  • BCG vaccine has been reported to have an activity of shifting CD4+ helper T cells to Th1 cells that are responsible for cell-mediated immunity by producing interferon- ⁇ and interleukin-2 (Cancer Immunol. Immunother. 39: 401-406, 1994; ibid. 40: 103-108, 1995).
  • the protein complex is composed of an antigen 85 complex-forming protein 85A with a molecular weight of about 30-32 kd (Infect. Immun. 57:3123-3130, 1989), an antigen 85 complex-forming protein 85B (J. Bacteriol. 170: 3847-3854, 1988) and an antigen 85 complex-forming protein 85C (Infect. Immun. 59: 3205-3212, 1991), which are major secretory proteins of Mycobacteria.
  • secretory proteins exhibit high homology of the gene sequence and the amino acid sequence and cross reactivity to monoclonal antibodies among the bacteria of the same genera such as Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium kansasii etc. irrespective of the species (Microbiol. Rev. 56: 648-661, 1992) and have, as common functions, the activity of binding to fibronectin and of mycolyl group transferase in the cell wall synthesis (Microbiol. Rev. 56: 648-661, 1992; Science 276: 1420-1422, 1997; Nat. Struct. Biol. 7: 887-88, 2000).
  • the antigen 85 complex-forming protein 85B is widely known as ⁇ antigen.
  • ⁇ antigen has been isolated and purified as a tuberculin reactive protein from the culture supernatant of Mycobacterium tuberculosis, and it has been revealed, there is an epitope in the molecule (Am. Rev. Respir. Dis. 130: 647-649, 1984; ibid. 132: 173-174, 1985; Microbiological Reviews 56: 648-661, 1992), and it has been reported that this ⁇ antigen has the above-mentioned effect of shifting to the Th1 cells (Infect. Immun. 60: 2880-2886, 1992).
  • Mycobacterium-derived ⁇ antigen such as BCG bacteria or analogs thereof or genes encoding them for the prevention or treatment of allergic diseases.
  • the present inventors have found that when an expression vector containing the ⁇ antigen-coding gene is applied to Caspase-1 transgenic mice, a mouse model which is at the Th2 type cytokine-dominant immunological state and which has a persistent atopic dermatitis-like dermatitis, the production of interleukin-4 was inhibited, blood levels of histamine and IgE were also suppressed, and skin diseases were improved, indicating that atopic dermatitis can be healed.
  • the ⁇ antigen protein was also found to heal atopic dermatitis in a similar manner.
  • the present inventors have revealed that the ⁇ antigen gene or the ⁇ antigen protein improves the Th2 type cytokine-dominant immunological state and can suppress and/or improve various conditions of allergic diseases, and thus is widely effective for the prevention or treatment of allergic diseases, and thereby have completed the present invention.
  • the present invention relates to a pharmaceutical composition for the prevention or treatment of allergic diseases comprising, as an active ingredient, the Mycobacterium-derived ⁇ antigen, an analog thereof, a mutant thereof having a function similar thereto, or a gene encoding them.
  • the present invention relates to a method of preventing or treating allergic diseases, said method comprising administering an effective amount of the Mycobacterium-derived ⁇ antigen, an analog thereof, a mutant thereof having a function similar thereto, or a gene encoding them to mammals including humans.
  • the present invention relates to the use of the Mycobacterium-derived ⁇ antigen, an analog thereof, a mutant thereof having a function similar thereto, or a gene encoding them for the production of a pharmaceutical composition for the prevention or treatment of allergic diseases.
  • the present invention uses an expression vector encoding the Mycobacterium-derived ⁇ antigen or an analog thereof, or the ⁇ antigen protein or an analog protein thereof for the prevention or treatment of atopic diseases such as atopic dermatitis, asthma, allergic rhinitis, and allergic conjunctivitis.
  • atopic diseases such as atopic dermatitis, asthma, allergic rhinitis, and allergic conjunctivitis.
  • analogs of the ⁇ antigen there can be mentioned an antigen 85 complex-forming protein 85A, antigen 85 complex-forming protein 85C and the like.
  • FIG. 1 shows the construction of an expression vector, constructed in Example 1, containing a gene encoding the ⁇ antigen for use as an active ingredient of a pharmaceutical composition for the prevention or treatment of allergic diseases of the present invention.
  • FIG. 2 is a drawing showing the effect of an expression vector containing a gene encoding the ⁇ antigen on the treatment of atopic dermatitis.
  • FIG. 3 is a graph showing serum levels of IgE when an expression vector containing a gene encoding the ⁇ antigen was administered to a mouse asthma model.
  • FIG. 4 is a graph showing protein concentrations in the alveolar lavage when an expression vector containing a gene encoding the ⁇ antigen was administered to a mouse asthma model.
  • FIG. 5 is a graph showing eosinophil counts in the alveolar lavage when an expression vector containing a gene encoding the ⁇ antigen was administered to a mouse asthma model.
  • FIG. 6 is a graph showing the degree of infiltration of eosinophils in the lung tissue when an expression vector containing a gene encoding the ⁇ antigen was administered to a mouse asthma model.
  • FIG. 7 is a graph showing the result of histological examination of the lung when an expression vector containing the gene encoding the ⁇ antigen was administered to a mouse asthma model.
  • the subject diseases of the present invention are allergic diseases, and more specifically allergic diseases caused by the Th2 type cytokine-dominant state.
  • the preferred subject allergic diseases of the present invention are specifically atopic diseases, for example atopic dermatitis, asthma, allergic rhinitis and allergic conjunctivitis, and specifically atopic dermatitis and asthma.
  • genes encoding the Mycobacterium-derived ⁇ antigen or an analog thereof refers to genes capable of expressing the ⁇ antigen protein, or ⁇ antigen protein analogs such as antigen 85 complex-forming protein 85A and antigen 85 complex-forming protein 85C. Specifically, there can be mentioned genes in the form of an expression vector containing a gene encoding the ⁇ antigen or an analog thereof. As genes encoding the ⁇ antigen, there can be illustrated genes encoding the ⁇ antigen derived from Mycobactera such as Mycobacterium kansasii (Infect. Immun. 58: 550-556, 1990), Mycobacterium avium (Infect. Immun.
  • mutant DNA may be a mutant DNA that hybridizes to this DNA under a stringent condition, or a mutant DNA comprising a DNA encoding a protein having an amino acid sequence in which one or more than one (preferably several) amino acid residues have been substituted, deleted and/or added to the amino acid sequence of the protein encoded by this DNA, wherein said mutant encodes a protein having the same function as the Mycobacterium kansasii-derived ⁇ antigen.
  • a specific method of obtaining a mutant DNA that hybridizes to this DNA under a stringent condition there can be mentioned the following method.
  • SSPE solution: EDTA sodium phosphate (SSPE) 1 ⁇ Denhardt: 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% bovine serum albumin
  • SDS 100 ⁇ g/ml ssDNA
  • 12.5 ng of a probe
  • the filter is washed in 1 ⁇ SSPE and a 0.5% SDS solution at 45° C./30 min, then in 0.1 ⁇ SSPE and a 0.5% SDS solution at 55° C./1 hour, and finally 0.1 ⁇ SSPE and a 0.5% SDS solution at 65° C./1 hour to eliminate the background completely, which is then exposed to an X-ray film (Fuji) at ⁇ 80° C. for 72 hours to determine the position of and isolate the corresponding colony and thus the mutant DNA can be obtained.
  • the above same function as the ⁇ antigen derived from Mycobacterium kansasii means to have a similar effect of preventing or treating allergic diseases.
  • mutants are those for which amino acid sequences encoded thereby usually have a homology of 60% or greater with the amino acid sequence of the ⁇ antigen protein, and preferably a homology of 75% or greater.
  • genes encoding the ⁇ antigen other than Mycobacterium kansasii they may be mutants thereof as well.
  • genes encoding the antigen 85 complex-forming protein 85A which is an analog of the ⁇ antigen there can be mentioned genes derived from the Mycobacteria similar to various Mycobacteria described above for the ⁇ antigen gene. More specifically, there can be mentioned a DNA encoding the antigen 85 complex-forming protein 85A derived from Mycobacterium tuberculosis (Infect. Immun. 57: 3123-3130, 1989).
  • genes encoding the antigen 85 complex-forming protein 85C as well, there can be mentioned a gene derived from various Mycobacteria, and more specifically, there can be mentioned a DNA encoding the antigen 85 complex-forming protein 85C derived from Mycobacterium tuberculosis (Infect. Immun.
  • DNAs as well, as described antibody they may be a mutant DNA that hybridizes to this DNA under a stringent condition, or a mutant DNA comprising a DNA encoding a protein having an amino acid sequence in which one or more than one (preferably several) amino acid residues have been substituted, deleted and/or added to the amino acid sequence of the protein encoded by this DNA, wherein said mutant encodes a protein having the same function as the antigen 85 complex-forming protein 85A or the antigen 85 complex-forming protein 85C.
  • the above DNAs can be cloned by a methyl such as RT-PCR reaction on mRNA derived from Mycobacteria using as PCR primers appropriate DNA segments based on the sequence information described in the above literature, sequence information of Genebank, etc. Chemical synthesis is also possible based on the amino acid sequence information. Furthermore, the above DNA mutants may be easily obtained using, for example, site-directed mutagenesis, PCR method, a common hybridization method, or the like.
  • the ⁇ antigen protein derived from Mycobacteria or derivatives thereof such as antigen 85 complex-forming protein 85A or antigen 85 complex-forming protein 85C or mutant proteins thereof can be used for the prevention or treatment of allergic diseases.
  • ⁇ antigens there can be mentioned proteins encoded by genes encoding the above-mentioned ⁇ antigen.
  • an ⁇ antigen which is encoded by the DNA having the base sequence derived from Mycobacterium kansasii described in SEQ ID NO: 1 and which has the amino acid sequence of SEQ ID NO: 2.
  • the ⁇ antigen having this amino acid sequence may be a mutant protein comprising an amino acid sequence in which one or more than one (preferably several) amino acid residues have been substituted, deleted and/or added to the amino acid sequence of SEQ ID NO: 2, said protein having the same function as the ⁇ antigen.
  • the ⁇ antigen derived from Mycobacterium other than Mycobacterium kansasii it may be a mutant protein comprising a protein in which one or more than one (preferably several) amino acid residues have been substituted, deleted and/or added to the amino acid sequence of those amino acid sequences, said protein having the same function as the ⁇ antigen.
  • antigen 85 complex-forming protein 85A or the antigen 85 complex-forming protein 85C as well, there can be mentioned the antigen 85 complex-forming protein 85A derived from Mycobacterium tuberculosis (Infect. Immun. 57: 3123-3130, 1989), the antigen 85 complex-forming protein 85C derived from Mycobacterium tuberculosis (Infect. Immun. 59: 3205-3212, 1991) and the like.
  • the analogs of these ⁇ antigen proteins may be mutants similar to those of the ⁇ antigen protein mentioned above.
  • proteins may be produced by a recombinant DNA technology using genes encoding them or by chemical synthesis.
  • Mycobacteria such as Mycobacterium kansasii may be cultured in a suitable medium, and from the culture liquid, the proteins may be purified by a known purification method (Scand. J. Immunol. 43: 202-209, 1996; J. Bacteriol. 170: 3847-3854, 1988; Hiroshima J. Med. Sci. 32: 1-8, 1983).
  • genes encoding the Mycobacterium-derived ⁇ antigen, a derivative thereof, or a mutant thereof are used for the prevention or treatment of allergic diseases, specifically they may be used in the form of an expression vector containing a gene encoding the ⁇ antigen, an analog thereof, or a mutant thereof.
  • Expression vectors containing these genes are roughly divided into two: cases when non-virus vectors are used, and cases when virus vectors are used.
  • Non-virus vectors may be any expression vectors as long as they can express and secrete genes that encode the ⁇ antigen, a derivative thereof, or a mutant thereof, and by way of example, there can be mentioned pCAGGS (Gene 108: 193-200, 1991), pBK-CMV, pcDNA3.1, pZeoSV (Invtrigen, Stratagene) etc.
  • virus vectors include recombinant adenovirus, retrovirus and the like. More specifically, there can be mentioned DNA viruses or RNA viruses such as detoxicated retrovirus, adenovirus, adeno-associated virus, helper virus, vaccinia virus, pox virus, poliovirus, Sindbis virus, Sendai virus, SV40, and human immunodeficiency virus (HIV).
  • DNA viruses or RNA viruses such as detoxicated retrovirus, adenovirus, adeno-associated virus, helper virus, vaccinia virus, pox virus, poliovirus, Sindbis virus, Sendai virus, SV40, and human immunodeficiency virus (HIV).
  • expression vectors By integrating a gene encoding the ⁇ antigen, an analog thereof or a mutant thereof into these vectors, expression vectors can be constructed.
  • These vectors may be generally administered to mammals including humans in the form of injections depending on the method of introducing into the living body.
  • viruses vectors may be administered as they are.
  • Injections may be prepared according to a standard method, and for example after they are dissolved in a suitable solvent (a buffer such as PBS, physiological saline, sterile water etc.), they may be filter-sterilized as desired with a filter etc. and then filled into a sterile container for formulation.
  • a suitable solvent a buffer such as PBS, physiological saline, sterile water etc.
  • Commonly used carriers may be added to the injections, as necessary. They may also be in the form of liposome formulations described below.
  • the expression vectors thus obtained for the treatment of allergic diseases can be administered in a standard method.
  • such methods include, for example, the lipofection method, the phosphate-calcium coprecipitation method, the DEAE-dextran method, the electroporation method, direct DNA injection methods using micro glass capillaries, and the like.
  • Such methods include, for example, gene introduction with internal type liposomes, gene introduction with electrostatic type liposomes, HVJ-liposome methods, improved HVJ-liposome methods (HVJ-AVE liposome methods), receptor-mediated gene introduction, methods of introducing DNA molecules into the cell together with carriers (metal particles) by a particle gun, in vivo electroporation, and the like.
  • HVJ-AVE liposome methods receptor-mediated gene introduction
  • methods of introducing DNA molecules into the cell together with carriers (metal particles) by a particle gun, in vivo electroporation, and the like There can also be used a method of dissolving a non-virus vector expression plasmid into physiological saline and using it as it is (the so-called naked-DNA direct introduction), a method of introduction with positively charged polymers, and the like.
  • the expression vector is a virus vector, it can be used as it is, or can be administered in the form of an injection as described above.
  • Expression vectors containing the gene encoding ⁇ antigen, an analog thereof or a mutant thereof are usually administered to the skin, muscles, the abdominal cavity etc. of mammals including humans.
  • the dosage may vary depending on the type of the expression vector, dosage form, dosage regimen, the subject patient, type of disease etc., and is generally, as the expression vector, about 0.005 to about 2 mg, preferably about 0.1 mg to about 1 mg, generally once daily over several months for a total of a few times.
  • Mycobacterium-derived ⁇ antigen protein, an analog protein thereof, or a mutant protein thereof when used as it is, it may generally be administered pareterally, for example intravenously, intramuscularly, intraperitoneally, subcutaneously, topically, etc. When administered parenterally, it may be given in the form of an injection, local application form, etc.
  • sterile solutions As injections, there can be mentioned sterile solutions, suspensions, or the like.
  • These formulations may be prepared by conventional methods in combination with pharmaceutically acceptable excipients, additives etc.
  • pharmaceutically acceptable excipients and additives there can be mentioned carriers, binders, flagrants, buffers, thickeners, colorants, stabilizers, emulsifying agents, dispersants, suspending agents, preservatives, and the like.
  • the ⁇ antigen protein may be added into a PBS buffer, physiological saline, sterile water etc., to which albumin may be added as desired, which is filter-sterilized with a filter etc. and then filled into sterile containers for formulation. They may also be lyophilized and dissolved to prepare injections at the time of administration. Ointments and creams used as topical applications may be formulated by adding the ⁇ antigen protein together with a thickener or a gelling agent to an aqueous or oily base.
  • Lotions may be formulated in a standard method by adding one or more of pharmaceutically acceptable stabilizers, suspending agents, emulsifying agents, dispersants, thickeners, colorants, flagrants etc. to an aqueous or oily base. Sprays, aerosols, patches, matrices, etc. can also be formulated according to standard methods. These local applications may contain, as desired, preservatives such as methyl hydroxybenzoate, propyl hydroxybenzoate, chloro cresol, and benzalkonium chloride, and bactericidal agents.
  • the dosage and the number of administration of the ⁇ antigen protein, a derivative thereof, or a mutant proteins thereof may vary depending on the symptom, age, body weight, dosage regimen, etc., and when administered as injections, generally about 1 mg to about 10 mg, preferably about 1 mg to about 5 mg is administered once or several times in divided doses. When topically administered, generally about 10 ⁇ g of the dose may be administered over several days.
  • ⁇ antigen gene ( ⁇ -K) of Mycobacterium kansasii comprising the base sequence from positions 390-1244 set forth in SEQ ID NO: 1 into the KpnI-ApaI site of pcDNA3.1 (Invitrogen CA), and then integrating it downstream of the CMV promoter and the TPA signal peptide, an expression vector pcDNA- ⁇ -K having the construction shown in FIG. 1 was constructed as an active ingredient of a pharmaceutical composition for the treatment of allergic diseases of the present invention (Infect. Immun. 58: 550-556, 1996).
  • mice that express skin-specific Caspase-1 and that are in the Th2-dominant immunological state were used (J. Immunol. 165: 997-1003, 2000; Nat. Immunol. 1: 132-137, 2000; Proc. Nah. Acod. Sci. USA 99;11340-11345, 2002). These mice developed atopic dermatitis from week 8 after birth.
  • FIG. 2 photographs of various CTg mice are shown.
  • a photograph in top left shows CTg mice at the onset of atopic dermatitis, and one in top right shows 12 week old littermate CTg mice that received no treatment.
  • a photograph in bottom left shows a result in which a littermate CTg mice was cured by the intramuscular injection of prednisolone for 7 days.
  • a photograph in bottom right shows the effect of treatment on week 8 after the intraperitoneal administration of the expression vector constructed in the above (1) to 4 week old CTg mice. After the administration of the expression vector, no development of diseases was seen during the observation period (one year).
  • Mycobacterium kansasii was cultured in the Sauton medium for 3 weeks, and the culture supernatant was precipitated with 80% ammonium sulfate to prepare a protein fraction.
  • the protein fraction was developed and separated by two dimensional electrophoresis on the gel, and from the corresponding spot on the gel, ⁇ antigen protein was extracted and purified (Scand. J. Immunol. 43: 202-209, 1996; J. Bacteriol. 170: 3847-3854, 1988; Hiroshima J. Med. Sci. 32: 1-8, 1983), and dissolved in PBS at a concentration of 1 mg/ml.
  • the expression vector (100 ⁇ g) constructed in Example 1-(I) and the heated BCG dead organism (100 ⁇ g) were intraperitoneally administered in equal amounts, respectively, on day 0 and day 14.
  • Serum levels of IgE, protein concentration in the alveolar lavage, eosinophil counts, eosinophil infiltration, and the histological image of the lung are shown in FIG. 3 to FIG. 7, respectively.
  • serum levels of IgE significantly decreased in the ⁇ antigen gene-containing expression vector administration group compared to the no treatment group.
  • protein concentration in the alveolar lavage which is an index of inflammatory reaction was apparently low in the expression vector administration group compared to the no treatment group and the BCG administration group.
  • the ⁇ antigen, an analog thereof, or an expression vector containing the gene encoding those analogs is administered to atopic dermatitis, histamine release is inhibited, and furthermore the production of IgE and interleukin-4 is suppressed, improving skin diseases and thereby exhibiting a highly effective effect for the treatment of atopic dermatitis. Furthermore, the ⁇ antigen, an analog protein thereof or an analog protein thereof also exhibits highly effective effect for the treatment of atopic dermatitis.
  • the ⁇ antigen, an analog protein thereof or an analog protein thereof is considered to exhibit the effect of improving the Th2 type cytokine-dominant immunological state, and therefore the ⁇ antigen, an analog thereof or the gene encoding an analog thereof, and the ⁇ antigen protein, an analog protein thereof or a mutant protein thereof is very effective for the prevention or treatment of atopic diseases such as atopic dermatitis, asthma, allergic rhinitis and allergic conjunctivitis, and more broadly allergic diseases.
  • atopic diseases such as atopic dermatitis, asthma, allergic rhinitis and allergic conjunctivitis, and more broadly allergic diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
US10/468,456 2001-02-20 2002-02-20 Novel medicinal use of alpha antigen or alpha antigen gene Abandoned US20040076639A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/352,342 US7524675B2 (en) 2001-02-20 2006-02-13 Pharmaceutical use of alpha antigen or alpha antigen gene
US11/896,977 US7622297B2 (en) 2001-02-20 2007-09-07 Pharmaceutical use of α antigen or α antigen gene
US12/405,844 US20090286734A1 (en) 2001-02-20 2009-03-17 Pharmaceutical Use of Alpha Antigen or Alpha Antigen Gene

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001-043291 2001-02-20
JP2001043291 2001-02-20
PCT/JP2002/001459 WO2002066055A1 (en) 2001-02-20 2002-02-20 NOVEL MEDICINAL USE OF α ANTIGEN OR α ANTIGEN GENE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/352,342 Division US7524675B2 (en) 2001-02-20 2006-02-13 Pharmaceutical use of alpha antigen or alpha antigen gene

Publications (1)

Publication Number Publication Date
US20040076639A1 true US20040076639A1 (en) 2004-04-22

Family

ID=18905480

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/468,456 Abandoned US20040076639A1 (en) 2001-02-20 2002-02-20 Novel medicinal use of alpha antigen or alpha antigen gene
US11/352,342 Expired - Lifetime US7524675B2 (en) 2001-02-20 2006-02-13 Pharmaceutical use of alpha antigen or alpha antigen gene
US11/896,977 Expired - Lifetime US7622297B2 (en) 2001-02-20 2007-09-07 Pharmaceutical use of α antigen or α antigen gene
US12/405,844 Abandoned US20090286734A1 (en) 2001-02-20 2009-03-17 Pharmaceutical Use of Alpha Antigen or Alpha Antigen Gene

Family Applications After (3)

Application Number Title Priority Date Filing Date
US11/352,342 Expired - Lifetime US7524675B2 (en) 2001-02-20 2006-02-13 Pharmaceutical use of alpha antigen or alpha antigen gene
US11/896,977 Expired - Lifetime US7622297B2 (en) 2001-02-20 2007-09-07 Pharmaceutical use of α antigen or α antigen gene
US12/405,844 Abandoned US20090286734A1 (en) 2001-02-20 2009-03-17 Pharmaceutical Use of Alpha Antigen or Alpha Antigen Gene

Country Status (7)

Country Link
US (4) US20040076639A1 (ja)
EP (1) EP1369127B1 (ja)
JP (1) JP4159362B2 (ja)
AT (1) ATE464065T1 (ja)
CA (1) CA2443502A1 (ja)
DE (1) DE60235971D1 (ja)
WO (1) WO2002066055A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573897A (zh) * 2009-11-02 2012-07-11 国立大学法人三重大学 使用副粘病毒载体的经鼻喷雾型结核疫苗
TWI500227B (zh) * 2009-10-16 2015-09-11 Himax Tech Ltd 積體電路之過度電性應力保護電路

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1369127B1 (en) * 2001-02-20 2010-04-14 MARUHO Co., Ltd. Novel medicinal use of alpha antigen or alpha antigen gene
JP5145550B2 (ja) * 2006-09-20 2013-02-20 国立大学法人三重大学 パラインフルエンザ２型ウイルスを用いた医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02308793A (ja) * 1989-05-22 1990-12-21 Ajinomoto Co Inc ミコバクテリウム・カンサシ由来のα抗原
EP0400973B1 (en) * 1989-05-31 1996-07-31 Ajinomoto Co., Inc. Mycobacterial secretory expression vectors and transformants
DE4422859C2 (de) * 1994-06-30 2000-10-05 Laves Arzneimittel Gmbh Wäßrige Zellextrakte aus Mykobacterien
DK0951289T3 (da) * 1996-12-18 2006-03-13 Stanford Rook Ltd Anvendelse af Mycobacterium vaccae til behandling af kronisk træthedssyndrom
JP2001518781A (ja) * 1997-03-28 2001-10-16 サイタクラナル、ファーマスーティクス、インク マイコバクテリウム組換えワクチン
AU757175B2 (en) * 1997-09-05 2003-02-06 Regents Of The University Of California, The Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
EP1369127B1 (en) * 2001-02-20 2010-04-14 MARUHO Co., Ltd. Novel medicinal use of alpha antigen or alpha antigen gene

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI500227B (zh) * 2009-10-16 2015-09-11 Himax Tech Ltd 積體電路之過度電性應力保護電路
CN102573897A (zh) * 2009-11-02 2012-07-11 国立大学法人三重大学 使用副粘病毒载体的经鼻喷雾型结核疫苗

Also Published As

Publication number Publication date
EP1369127A4 (en) 2008-01-30
US20060153880A1 (en) 2006-07-13
DE60235971D1 (de) 2010-05-27
EP1369127A1 (en) 2003-12-10
JP4159362B2 (ja) 2008-10-01
CA2443502A1 (en) 2002-08-29
EP1369127B1 (en) 2010-04-14
WO2002066055A1 (en) 2002-08-29
JPWO2002066055A1 (ja) 2004-06-17
US7622297B2 (en) 2009-11-24
US20080132463A1 (en) 2008-06-05
US20090286734A1 (en) 2009-11-19
US7524675B2 (en) 2009-04-28
ATE464065T1 (de) 2010-04-15

Similar Documents

Publication Publication Date Title
US9717782B2 (en) Methods for producing an immune response to tuberculosis
KR20120014176A (ko) 재활성화를 예방하기 위한 결핵 백신
AU2017285424B2 (en) Tuberculosis compositions and methods of treating or preventing tuberculosis
KR20000037134A (ko) 결핵균 감염을 치료 및 진단하기 위한 조성물 및 그 방법
JP2017513860A (ja) 新規結核菌（ｍ．ｔｕｂｅｒｃｕｌｏｓｉｓ）ワクチン
US7622297B2 (en) Pharmaceutical use of α antigen or α antigen gene
JP2019521095A (ja) 二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
EP3281638A1 (en) Mycobacterial antigen composition
Minami et al. Pulmonary granulomas caused experimentally in mice by a recombinant triggerfactor protein of Propionibacterium acnes
RU2659149C2 (ru) Композиции и способы для лечения активной инфекции mycobacterium tuberculosis
JP2002514385A (ja) ミコバクテリウム・バッケー由来の組成物およびその使用法
WO2009064825A2 (en) Generation of new bcg vaccine strains protecting against the establishment of latent mycobacterium tuberculosis infection and reactivation from the latent or persistent state
Nagarajan et al. SopB of Salmonella enterica serovar Typhimurium is a potential DNA vaccine candidate in conjugation with live attenuated bacteria
Souza et al. Therapeutic effect of DNA vaccine encoding the 60-kDa-heat shock protein from Paracoccidoides brasiliensis on experimental paracoccidioidomycosis in mice
EP2042191A1 (en) Anaplastic Lymphoma Kinase (ALK) as oncoantigen for lymphoma vaccination
JP5994127B2 (ja) 新規な組換えｂｃｇワクチン
US20140212455A1 (en) Recombinant bcg strains with enhanced ability to inhibit intracellular mycobacterial growth
US11566055B2 (en) Composition for preventing or treating autoimmune disease based on LRR domain of NLRX1 protein
US6406704B1 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
Mudalagiriyappa et al. Sialophorin is an essential host element for vaccine immunity against pulmonary fungal infections
Eishi Propionibacterium acnes as a cause of sarcoidosis
KR20010033132A (ko) 미코박테리움 바카이에서 유도한 조성물 및 이의 이용방법
Coler Identification and characterization of novel antigen genes of Mycobacterium tuberculosis
JP2015510887A (ja) 化膿性鼻副鼻腔炎の処置のためのチモシンαの使用

Legal Events

Date Code Title Description
AS Assignment

Owner name: MARUHO CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YASUTOMI, YASUHIRO;MIZUTANI, HITOSHI;REEL/FRAME:014751/0751

Effective date: 20030805

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION